Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -41051.94% is 20% below its 4-year average of -34240.36%, near the high end of its 4-year range (-249900.74%–-13997.67%).
1.08% above its 12-month average of -41500.77%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -27846.16%.
EBITDA MARGIN
-41051.94%
EBITDA MARGIN AVG TTM
-41500.77%
EBITDA MARGIN AVG 3Y
-31133.29%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+1.08%
CURRENT VS 3Y AVG
-31.86%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Cardio Diagnostics Holdings, Inc.
Market Cap
$6.10M
EBITDA Margin
-41051.94%
TTM Avg
-41500.77%
3Y Avg
-31133.29%
5Y Avg
N/A
Market Cap
$6.10M
EBITDA Margin
-729.87%
TTM Avg
-884.05%
3Y Avg
-981.20%
5Y Avg
-851.95%
Market Cap
$6.09M
EBITDA Margin
-417.17%
TTM Avg
-417.17%
3Y Avg
-417.17%
5Y Avg
-417.17%
Market Cap
$6.03M
EBITDA Margin
-9081.41%
TTM Avg
-6199.48%
3Y Avg
-3862.58%
5Y Avg
-3269.64%
Market Cap
$6.34M
EBITDA Margin
-110.02%
TTM Avg
-99.60%
3Y Avg
-109.65%
5Y Avg
-93.07%
Market Cap
$6.44M
EBITDA Margin
-485.73%
TTM Avg
-485.73%
3Y Avg
-485.73%
5Y Avg
-485.73%
Market Cap
$6.72M
EBITDA Margin
-430.70%
TTM Avg
-678.73%
3Y Avg
-962.21%
5Y Avg
-5357.45%
Market Cap
$6.74M
EBITDA Margin
-9012.26%
TTM Avg
-10323.55%
3Y Avg
-8965.35%
5Y Avg
-8208.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | $6.10M | -41051.94% | -41500.77% | -31133.29% | N/A |
| Femasys Inc. (FEMY)vs › | $6.10M | -729.87% | -884.05% | -981.20% | -851.95% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | -417.17% | -417.17% | -417.17% | -417.17% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | -9081.41% | -6199.48% | -3862.58% | -3269.64% |
| Biomerica, Inc. (BMRA)vs › | $6.34M | -110.02% | -99.60% | -109.65% | -93.07% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | -485.73% | -485.73% | -485.73% | -485.73% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -430.70% | -678.73% | -962.21% | -5357.45% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -9012.26% | -10323.55% | -8965.35% | -8208.29% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -10.17% | -10.02% | -12.29% | -11.98% |
Gross Margin
100.0%
EBITDA Margin
-41051.9%
Operating Margin
-43737.5%
Net Margin
-44771.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -27846.16% |
| 2026-03-31 | -63066.60% |
| 2025-12-31 | -38513.22% |
| 2025-09-30 | -56812.92% |
| 2025-06-30 | -21264.96% |
| 2025-03-31 | -160131.91% |
| 2024-12-31 | -31738.25% |
| 2024-09-30 | -20158.81% |
| 2024-06-30 | -15264.82% |
| 2024-03-31 | -25927.37% |
| 2023-12-31 | -27875.35% |
| 2023-09-30 | -13997.67% |
| 2023-06-30 | -147730.32% |
| 2022-12-31 | -249900.74% |
| 2021-12-31 | -68418.20% |
